Lamivudine
novel
cytosine
analogue
inhibitory
effects
hepatitis B virus
in vitro
in vivo
single-blind
placebo-controlled study
effectiveness
safety
Chinese hepatitis B surface antigen
HBsAg
carriers
Chinese
HBsAg
carriers
randomized
placebo
patients
lamivudine
orally
dosages
patients
dosage
drug
weeks
patients
monitored
clinically
biochemically
serologically
weeks
drug treatment
patients
lamivudine
decrease
hepatitis B virus
placebo
lamivudine
effective
induced
suppression
HBV DNA
therapy
HBV DNA values
pretreatment
levels
weeks
cessation
therapy
hepatitis B e antigen
aminotransferase levels
adverse events
lamivudine
effective
suppression
HBV DNA
Chinese
HBsAg
carriers
suppression
reversible
Studies
long-term
lamivudine
administration
prolonged
suppression
HBV DNA
